

## REMARKS

Reconsideration of this application, as amended, is respectfully requested. Claims 1, 4, 5, 16, 19, 20, 41-44, 47, 48, 64 and 67-69 have been cancelled. Claims 6, 11, 21, 26, 29, 30, 49, 54, and 59 have been amended. New claims 70-77 have been added. With this amendment, claims 6, 9-11, 14, 15, 21, 24-26, 29, 30, 40, 49, 52-54, 57-59, 62, 63, 65, 66, and 70-77 are pending. All amendments find support in the application as originally filed. All amendments are made without prejudice or disclaimer and Applicants reserve the right to prosecute any cancelled or otherwise unclaimed subject matter of this patent application in this or another application. Based on the amendment and remarks presented herein, applicants submit that the application is now in condition for allowance.

### Amendment to the Claims

The Office Action indicated that claims 11, 14-16, 19, 20, 40-43, 54, 57, 58 and 66 would be allowable if rewritten in independent form to including all of the limitations of the base claim and any intervening claims. Claims 11 and 54, upon which the remaining pending claims directly or indirectly depend, have been rewritten as suggested by the Examiner. New claims 70-77 capture other unclaimed material or further define the angiogenesis-associated antigen, the at least one additional tumor-associated antigen, and / or the co-stimulatory component. Applicants respectfully submit that the claims are now in condition for allowance.

### Priority

Applicants believe that the subject matter of claims 67-69 is entitled to the earliest claimed priority date of this application (60/394,346 filed July 3, 2002). However, claims 67-69 have been cancelled; the issue is therefore moot.

### Rejections Under 35 U.S.C § 103(a)

Claims 1, 4, 5, 21, 24-26, 29, 30, 44, 47 and 48 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Gish (U.S. Pat. No. 6,780,586) and Ghose et al. (Human Gene Therapy, 2000, Vol. 11, pp. 1289-1301). Claims 1, 4, 5, 47 and 48 have been cancelled; the rejection is therefore moot as to these claims. Claims 21, 24-26, 29, 30, 44 have been amended to include only subject matter indicated by the Office Action to be non-obvious and allowable. Accordingly, withdrawal of the rejection of claims 21, 24-26, 29, 30, 44, 59, 62-64 and 67-69 is respectfully requested.

Claims 1, 4, 5, 21, 24-26, 29, 30, 44, 47, 48, 59, 62-64 and 67-69 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Gish (U.S. Pat. No. 6,780,586) and Ghose et al. (Human Gene Therapy, 2000, Vol. 11, pp. 1289-1301) and further in view of Paoletti et al. (U.S. Pat. No. 5,833,975). Claims 1, 4, 5, 47, 48, and 67-69 have been cancelled; the rejection is therefore moot as to these claims. Claims 21, 24-26, 29, 30, 44, 59, 62-64 and 67-69 have been amended to include only subject matter indicated by the Office Action to be non-obvious and allowable. Accordingly, withdrawal of the rejection of claims 21, 24-26, 29, 30, 44, 59, 62-64 and 67-69 is respectfully requested.

Claims 1, 4-6, 9, 10, 21, 24-26, 29, 30, 44, 47-49, 52, 53, 59, and 62-65 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Gish (U.S. Pat. No. 6,780,586) and Ghose et al. (Human Gene Therapy, 2000, Vol. 11, pp. 1289-1301) and further in view of McArthur et al. (U.S. Pat. No. 7,217,421). Claims 1, 4, 5, 44, 47, 48 and 64 have been cancelled; the rejection as to these claims is therefore moot. Claims 6, 9, 10, 21, 24-26, 29, 30, 49, 52, 53, 59, 62, 63, and 65 have been amended to include only subject matter indicated by the Office Action to be non-obvious and allowable. Accordingly, the rejections of claims 21, 24-26, 29, 30, 44 are no longer applicable. Withdrawal of these rejections is therefore respectfully requested.

### CONCLUSIONS

Consideration and entry of this response is respectfully requested. Applicants believe the claims are now in condition for allowance, and respectfully request that a Notice of Allowance be issued as soon as possible. The examiner is encouraged to contact the undersigned if it is believed doing so would assist in the examination of this application

Respectfully submitted,

Dated: March 16, 2009

/Patrick J. Halloran/  
Patrick J. Halloran  
Reg. No. 41,053

Patrick J. Halloran, Ph.D., J.D.  
3141 Muirfield Road  
Center Valley, PA 18034  
Tel: 610-984-4751  
e-mail: pat@pathalloran.com